CK-302 is an investigational fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. GITR is a co-stimulatory molecule of the TNF receptor family and is expressed on activated T cells, B cells, natural killer and regulatory T cells.
GITR-specific agonistic monoclonal antibodies have been shown to induce tumor regression in vivo through the activation of CD4+ T-cells, CD8+ T-cells and NK cells in a number of tumor models. We licensed the exclusive worldwide rights to anti-GITR antibodies from Dana-Farber Cancer Institute in March 2015.
We plan to develop our anti-GITR antibody in solid tumor oncology indications where scientific literature supports the potential for an anti-GITR to be effective or in combination with an anti-PD-L1 antibody as well as other anti-tumor immune response potentiating compounds and targeted therapies.